4.7 Article

Investigating the suitability of in vitro cell lines as models for the major subtypes of epithelial ovarian cancer

期刊

出版社

FRONTIERS MEDIA SA
DOI: 10.3389/fcell.2023.1104514

关键词

Ovarian cancer; cell line; subtype classification; RNA-Seq-RNA sequencing; Non-negative matrix factorization (NMF); correlation

向作者/读者索取更多资源

Epithelial ovarian cancer (EOC) is a highly heterogeneous disease with five major histological subtypes. Cell line models that accurately represent these subtypes are essential for pre-clinical EOC research. This study aimed to generate a reference dataset of cell lines representative of the major EOC subtypes and identified lines with high molecular similarity to primary tumors. The findings highlight the importance of selecting suitable cell line models to maximize the clinical relevance of experiments.
Epithelial ovarian cancer (EOC) is the most fatal gynaecological malignancy, accounting for over 200,000 deaths worldwide per year. EOC is a highly heterogeneous disease, classified into five major histological subtypes-high-grade serous (HGSOC), clear cell (CCOC), endometrioid (ENOC), mucinous (MOC) and low-grade serous (LGSOC) ovarian carcinomas. Classification of EOCs is clinically beneficial, as the various subtypes respond differently to chemotherapy and have distinct prognoses. Cell lines are often used as in vitro models for cancer, allowing researchers to explore pathophysiology in a relatively cheap and easy to manipulate system. However, most studies that make use of EOC cell lines fail to recognize the importance of subtype. Furthermore, the similarity of cell lines to their cognate primary tumors is often ignored. Identification of cell lines with high molecular similarity to primary tumors is needed in order to better guide pre-clinical EOC research and to improve development of targeted therapeutics and diagnostics for each distinctive subtype. This study aims to generate a reference dataset of cell lines representative of the major EOC subtypes. We found that non-negative matrix factorization (NMF) optimally clustered fifty-six cell lines into five groups, putatively corresponding to each of the five EOC subtypes. These clusters validated previous histological groupings, while also classifying other previously unannotated cell lines. We analysed the mutational and copy number landscapes of these lines to investigate whether they harboured the characteristic genomic alterations of each subtype. Finally we compared the gene expression profiles of cell lines with 93 primary tumor samples stratified by subtype, to identify lines with the highest molecular similarity to HGSOC, CCOC, ENOC, and MOC. In summary, we examined the molecular features of both EOC cell lines and primary tumors of multiple subtypes. We recommend a reference set of cell lines most suited to represent four different subtypes of EOC for both in silico and in vitro studies. We also identify lines displaying poor overall molecular similarity to EOC tumors, which we argue should be avoided in pre-clinical studies. Ultimately, our work emphasizes the importance of choosing suitable cell line models to maximise clinical relevance of experiments.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Oncology

3D Functional Genomics Screens Identify CREBBP as a Targetable Driver in Aggressive Triple-Negative Breast Cancer

Barrie Peck, Philip Bland, Ioanna Mavrommati, Gareth Muirhead, Hannah Cottom, Patty T. Wai, Sarah L. Maguire, Holly E. Barker, Eamonn Morrison, Divya Kriplani, Lu Yu, Amy Gibson, Giulia Falgari, Keith Brennan, Gillian Farnie, Richard Buus, Rebecca Marlow, Daniela Novo, Eleanor Knight, Naomi Guppy, Daniela Kolarevic, Snezana Susnjar, Natasa Medic Milijic, Kalnisha Naidoo, Patrycja Gazinska, Ioannis Roxanis, Sunil Pancholi, Lesley-Ann Martin, Erle M. Holgersen, Maggie C. U. Cheang, Farzana Noor, Sophie Postel-Vinay, Gerard Quinn, Simon McDade, Lukas Krasny, Paul Huang, Frances Daley, Fredrik Wallberg, Jyoti S. Choudhary, Syed Haider, Andrew N. Tutt, Rachael Natrajan

Summary: This study highlights the identification of CREBBP as a novel driver in aggressive TNBC, with associated genetic vulnerability in tumor cells with alterations in CREBBP, and provides a preclinical rationale for assessing CREBBP alterations as a biomarker of CDK4/6 inhibitor response in a new patient population. Targeting CREBBP alterations with clinical CDK4/6 inhibitors selectively impairs growth in spheroids, cell line xenografts, and patient-derived models from multiple tumor types.

CANCER RESEARCH (2021)

Article Oncology

Research Strategies for Low-Survival Cancers

Caroline Conway, Denis M. Collins, Amanda McCann, Kellie Dean

Summary: The report provides an overview of research presented at the 56th annual conference of the Irish Association for Cancer Research, focusing on low-survival cancers. It emphasizes the need for new and improved treatment strategies for these challenging cancers, highlighting ongoing research efforts aimed at improving patient outcomes.

CANCERS (2021)

Article Biochemistry & Molecular Biology

SynLeGG: analysis and visualization of multiomics data for discovery of cancer 'Achilles Heels' and gene function relationships

Mark Wappett, Adam Harris, Alexander L. R. Lubbock, Ian Lobb, Simon McDade, Ian M. Overton

Summary: Achilles' heel relationships in cancer cells can be identified using the SynLeGG tool, which analyzes omics data to discover genetic dependency relationships. The tool relies on the MultiSEp algorithm for unsupervised cell line clustering and shows favorable performance in comparison to other approaches. It also offers tissue-specific analysis and provides additional information for interpretation and drug target prioritization.

NUCLEIC ACIDS RESEARCH (2021)

Article Oncology

Molecular and cellular characterization of two patient-derived ductal carcinoma in situ (DCIS) cell lines, ETCC-006 and ETCC-010

Julia Samson, Magdalina Derlipanska, Oza Zaheed, Kellie Dean

Summary: This study conducted a molecular and cellular characterization of two patient-derived DCIS cell lines, ETCC-006 and ETCC-010, revealing differences in migration and anchorage-independent growth capabilities compared to other DCIS cell lines. Despite being isogenic, less than 30% of differentially expressed transcripts overlapped between the two lines, with enrichment in pathways involving receptor tyrosine kinases and DNA replication/cell cycle programs.

BMC CANCER (2021)

Article Cell Biology

Exploring Evidence of Non-coding RNA Translation With Trips-Viz and GWIPS-Viz Browsers

Oza Zaheed, Stephen J. Kiniry, Pavel V. Baranov, Kellie Dean

Summary: The detection of translation in non-coding RNAs provides an opportunity for identifying novel bioactive peptides and microproteins, with ribosome profiling and mass spectrometry being the main methods used. Public data mining is an attractive strategy for this purpose, but it requires intensive data processing. Researchers in this study used tools like OpenProt, GWIPS-viz, and Trips-Viz to explore the translation in non-coding RNAs, and found evidence suggesting that the MTLN mRNA, previously misannotated, likely encodes only a short proteoform.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Article Cell Biology

Molecular Subtyping Resource: a user-friendly tool for rapid biological discovery from transcriptional data

Baharak Ahmaderaghi, Raheleh Amirkhah, James Jackson, Tamsin R. M. Lannagan, Kathryn Gilroy, Sudhir B. Malla, Keara L. Redmond, Gerard Quinn, Simon S. McDade, Tim Maughan, Simon Leedham, Andrew S. D. Campbell, Owen J. Sansom, Mark Lawler, Philip D. Dunne

Summary: We have developed an open source data analysis platform called MouSR, which allows 'wet-lab' users to easily analyze transcriptional data without requiring programming skills. This platform provides a user-friendly interface and a suite of molecular characterization options for rapid transcriptomic analysis, addressing a major bottleneck in biological discovery.

DISEASE MODELS & MECHANISMS (2022)

Article Oncology

Functional Genomic Identification of Predictors of Sensitivity and Mechanisms of Resistance to Multivalent Second-Generation TRAIL-R2 Agonists

Vera Grinkevitch, Mark Wappett, Nyree Crawford, Stacey Price, Andrea Lees, Christopher McCann, Katherine McAllister, Jochen Prehn, Jamie Young, Jess Bateson, Lewis Gallagher, Magali Michaut, Vivek Iyer, Aikaterini Chatzipli, Syd Barthorpe, Daniel Ciznadija, Ido Sloma, Amy Wesa, David A. Tice, Lodewyk Wessels, Mathew Garnett, Daniel B. Longley, Ultan McDermott, Simon S. McDade

Summary: Second-generation TRAIL-R2 agonists face two major clinical challenges: lack of predictive biomarkers and development of resistance. This study identifies caspase-8:FLIP(L) and caspase-8:MCL-1 ratios as potential predictive biomarkers for second-generation TRAIL-R2 agonists, and loss of key effectors like FADD and caspase-8 as likely drivers of clinical resistance in solid tumors.

MOLECULAR CANCER THERAPEUTICS (2022)

Article Oncology

Characterizing and Exploiting Tumor Microenvironments to Optimize Treatment Outcomes

Emma H. Allott, Kellie Dean, Tracy Robson, Claire Meaney

Summary: The 57th Annual Conference of the Irish Association for Cancer Research focused on the tumor microenvironment and its impact on tumor growth and progression. The complexity of the microenvironment was highlighted, along with its potential as a target for new cancer treatments. Discussions also emphasized the importance of modeling the surrounding environment for a more comprehensive understanding of tumorigenesis.

CANCERS (2021)

Article Biochemical Research Methods

classifieR a flexible interactive cloud-application for functional annotation of cancer transcriptomes

Gerard P. Quinn, Tamas Sessler, Baharak Ahmaderaghi, Shauna Lambe, Harper VanSteenhouse, Mark Lawler, Mark Wappett, Bruce Seligmann, Daniel B. Longley, Simon S. McDade

Summary: classifieR is an easy-to-use web application based on R-Shiny, designed to facilitate flexible and rapid single sample annotation of transcriptional profiles from cancer patient samples in laboratories. It provides information on the molecular makeup of samples, as well as analysis of prognosis, druggability, and discovery of new information.

BMC BIOINFORMATICS (2022)

Article Gastroenterology & Hepatology

Activation of innate-adaptive immune machinery by poly(I:C) exposes a therapeutic vulnerability to prevent relapse in stroma-rich colon cancer

Shania M. Corry, Amy M. B. McCorry, Tamsin R. M. Lannagan, Niamh A. Leonard, Natalie C. Fisher, Ryan M. Byrne, Petros Tsantoulis, Xabier Cortes-Lavaud, Raheleh Amirkhah, Keara L. Redmond, Aoife J. McCooey, Sudhir B. Malla, Emily Rogan, Svetlana Sakhnevych, Michael A. Gillespie, Mark White, Susan D. Richman, Rene-Filip Jackstadt, Andrew D. Campbell, Sarah Maguire, Simon S. McDade, Daniel B. Longley, Maurice B. Loughrey, Helen G. Coleman, Emma M. Kerr, Sabine Tejpar, Timothy Maughan, Simon J. Leedham, Donna M. Small, Aideen E. Ryan, Owen J. Sansom, Mark Lawler, Philip D. Dunne

Summary: This study identifies and validates a HiFi-specific prognostic signature (HPS) based on STAT1-related signaling in the stroma-rich subtype of colon cancer. The HPS is associated with immune cell and antigen processing in stroma-rich colon cancer and treatment with the TLR3 agonist poly(I:C) can enhance the HPS signaling and reduce liver metastases.
Article Oncology

Bcl-xL Is a Key Mediator of Apoptosis Following KRASG12C Inhibition in KRASG12C-mutant Colorectal Cancer

Hajrah Khawaja, Rebecca Briggs, Cheryl H. Latimer, Mustasin Rassel, Dary Griffin, Lyndsey Hanson, Alberto Bardelli, Frederica Di Nicolantonio, Simon S. McDade, Christopher J. Scott, Shauna Lambe, Manisha Maurya, Andreas U. Lindner, Jochen H. M. Prehn, Jose Sousa, Chris Winnington, Melissa J. LaBonte, Sarah Ross, Sandra Van Schaeybroeck

Summary: Novel covalent inhibitors of KRASG12C have shown limited response rates in patients with KRASG12C-mutant colorectal cancer. In this study, researchers found that the combination of AZ'1569 and a Bcl-xL inhibitor led to a dramatic and universal apoptosis, suggesting a potential therapeutic strategy for patients with KRAS G12C-mutant colorectal cancer.

MOLECULAR CANCER THERAPEUTICS (2023)

Article Cell Biology

Autocrine activation of MAPK signaling mediates intrinsic tolerance to androgen deprivation in LY6D cancer cells

Ivana Steiner, Teresita del N. J. Flores-Tellez, Renaud Mevel, Amin Ali, Pengbo Wang, Pieta Schofield, Caron Behan, Nicholas Forsythe, Garry Ashton, Catherine Taylor, Ian G. Mills, Pedro Oliveira, Simon S. McDade, Dietmar M. Zaiss, Ananya Choudhury, Georges Lacaud, Esther Baena

Summary: Conditional deletion of PTEN gene in prostate cells leads to an increase in LY6D+ progenitor cells, resulting in the formation of castration-resistant prostate cancer with unmet clinical need. LY6D+ tumor cells are enriched in high-grade and androgen-resistant prostate cancer, providing clinical evidence for their contribution to advanced disease. Interfering with the MAPK signaling pathway can prevent the progression of castration-resistant prostate cancer.

CELL REPORTS (2023)

暂无数据